Harrow (HROW) said Wednesday it has relaunched Verkazia 0.1% for the treatment of vernal keratoconjunctivitis, an allergic eye disease that mainly affects children.
Verkazia, or cyclosporine ophthalmic emulsion, is now backed by a commercial strategy that covers physician education, patient access, and affordability initiatives to ensure its supply and accessibility, Harrow said.
Shares of Harrow were down 1.3% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments